Insulet Gains 77.2% in a Year: What's Driving the Rally?
PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.
Should Boston Scientific Stock Be in Your Portfolio Right Now?
BSX's global expansion and MedSurg growth boost Q2 momentum, though currency and macro headwinds weigh on the same.
Here's Why Idexx Laboratories ( IDXX ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teleflex Stock Gains Following Barrigel's Launch in Japan
TFX stock jumps 3.7% after launching Barrigel in Japan, marking a milestone in its global expansion strategy.
PAHC Stock Up 76.4% in a Year: What's Driving the Rally?
Phibro Animal Health's 76.4% stock surge is fueled by strong sales recovery, global growth and a robust balance sheet.
Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up
LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.
$1000 Invested In IDEXX Laboratories 15 Years Ago Would Be Worth This Much Today - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories IDXX has outperformed the market over the past 15 years by 10.61% on an annualized basis producing an average annual return of 23.26%. Currently, IDEXX Laboratories has a market capitalization of $52.86 billion.
Here's How Much a $1000 Investment in Idexx Laboratories Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
A Closer Look at IDEXX Laboratories's Options Market Dynamics - IDEXX Laboratories ( NASDAQ:IDXX )
Whales with a lot of money to spend have taken a noticeably bearish stance on IDEXX Laboratories. Looking at options history for IDEXX Laboratories IDXX we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 12% of the investors opened trades with bullish ...
Veterinary Diagnostics Market is expected to generate a revenue of USD 4.52 Billion by 2031, Globally, at 6.59% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- The Global Veterinary Diagnostics Market Size is projected to grow at a CAGR of 6.59% from 2024 to 2031, according to a new report published by Verified Market Research®.
Is Idexx ( IDXX ) a Solid Growth Stock? 3 Reasons to Think "Yes"
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Idexx Laboratories ( IDXX ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Idexx Laboratories ( IDXX ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is the Market Bullish or Bearish on IDEXX Laboratories? - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories's IDXX short percent of float has risen 3.9% since its last report. The company recently reported that it has 2.64 million shares sold short, which is 4.26% of all regular shares that are available for trading.
Tesla, Delta Air, IDEXX Laboratories And More On CNBC's 'Final Trades' - IDEXX Laboratories ( NASDAQ:IDXX ) , Delta Air Lines ( NYSE:DAL )
Jim Lebenthal names Delta Air Lines as his final trade. Bryn Talkington recommends sticking with Tesla. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday.
Here's How Much $1000 Invested In IDEXX Laboratories 20 Years Ago Would Be Worth Today - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories IDXX has outperformed the market over the past 20 years by 4.25% on an annualized basis producing an average annual return of 12.73%. Currently, IDEXX Laboratories has a market capitalization of $55.35 billion.
Wayfair, CommScope Holding, Steelcase, IDEXX Laboratories And Other Big Stocks Moving Higher On Monday - Blade Air Mobility ( NASDAQ:BLDE ) , American Eagle Outfitters ( NYSE:AEO )
U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Monday. Shares of Wayfair Inc. W rose sharply during Monday's session following better-than-expected second-quarter financial results. The e-commerce company reported adjusted earnings per share of 87 cents, beating ...
IDEXX Surpasses Earnings Expectations, Justifying Premium Valuation - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Q2 earnings of $3.50 beat estimates; revenue rose 11% to $1.11 billion, driven by 11% growth in Companion Animal Group sales. Full-year EPS guidance raised to $12.40-$12.76 vs. $12.13 consensus; revenue forecast increased to $4.21-$4.28 billion.
IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
IDXX posts double-digit Q2 revenue growth, beats EPS estimates and lifts the full-year outlook as margins rise sharply.
Idexx ( IDXX ) Q2 Revenue Jumps 11%
Idexx Laboratories ( NASDAQ:IDXX ) , a leading provider of veterinary diagnostics and software, released its second-quarter earnings on August 4, 2025. The company's update for the quarter highlighted much stronger than anticipated financial results, led by rapid adoption of new diagnostic ...
Idexx Laboratories ( IDXX ) Tops Q2 Earnings and Revenue Estimates
Idexx (IDXX) delivered earnings and revenue surprises of +9.67% and +4.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences ( IART ) Beats Q2 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of +4.65% and +5.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Idexx ( IDXX ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Idexx (IDXX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
AxoGen ( AXGN ) Earnings Expected to Grow: Should You Buy?
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Peering Into IDEXX Laboratories's Recent Short Interest - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories's IDXX short percent of float has risen 3.9% since its last report. The company recently reported that it has 2.64 million shares sold short, which is 4.26% of all regular shares that are available for trading.
Idexx Laboratories ( IDXX ) Earnings Expected to Grow: Should You Buy?
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEXX to Release Q2 Earnings: What's in Store for the Stock?
IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.
Should You Invest in the First Trust Water ETF ( FIW ) ?
Sector ETF report for ...
Should Franklin U.S. Mid Cap Multifactor Index ETF ( FLQM ) Be on Your Investing Radar?
Style Box ETF report for ...
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories IDXX has outperformed the market over the past 10 years by 12.19% on an annualized basis producing an average annual return of 23.57%. Currently, IDEXX Laboratories has a market capitalization of $43.85 billion.
Is atai Life Sciences ( ATAI ) Stock Outpacing Its Medical Peers This Year?
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Idexx ( IDXX ) is an Incredible Growth Stock: 3 Reasons Why
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors
Berberian brings significant technology leadership and cybersecurity expertise Berberian brings significant technology leadership and cybersecurity expertise ...
Here's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade Ago
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 20 Years - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories IDXX has outperformed the market over the past 20 years by 2.86% on an annualized basis producing an average annual return of 11.3%. Currently, IDEXX Laboratories has a market capitalization of $44.21 billion.
Will Idexx ( IDXX ) Beat Estimates Again in Its Next Earnings Report?
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Are Medical Stocks Lagging atai Life Sciences ( ATAI ) This Year?
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Two US Lawmakers On The Armed Services Committee Quietly Snapped Up L3Harris Shares Leading Up To Iran Tensions: 'This Shouldn't Be Legal' - IDEXX Laboratories ( NASDAQ:IDXX ) , L3Harris Technologies ( NYSE:LHX )
Two U.S. lawmakers are being called out after disclosing their stock purchases involving defense contractor L3Harris Technologies Inc. LHX, in the lead up to conflict with Iran, while serving on the Congressional Armed Services Committee.
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories IDXX has outperformed the market over the past 15 years by 8.52% on an annualized basis producing an average annual return of 20.39%. Currently, IDEXX Laboratories has a market capitalization of $42.54 billion.
What Does the Market Think About IDEXX Laboratories? - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories's IDXX short percent of float has risen 5.63% since its last report. The company recently reported that it has 3.03 million shares sold short, which is 4.88% of all regular shares that are available for trading.
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories IDXX has outperformed the market over the past 15 years by 8.47% on an annualized basis producing an average annual return of 20.35%. Currently, IDEXX Laboratories has a market capitalization of $40.65 billion.
Should You Invest in the First Trust Water ETF ( FIW ) ?
Sector ETF report for ...
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories IDXX has outperformed the market over the past 20 years by 3.16% on an annualized basis producing an average annual return of 11.41%. Currently, IDEXX Laboratories has a market capitalization of $40.59 billion.
Is Franklin U.S. Mid Cap Multifactor Index ETF ( FLQM ) a Strong ETF Right Now?
Smart Beta ETF report for ...
If You Invested $1000 in Idexx Laboratories a Decade Ago, This is How Much It'd Be Worth Now
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Is IDEXX Laboratories ( IDXX ) Outperforming Other Medical Stocks This Year?
Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
IDXX Q1 Earnings Beat, FY25 View Raised, Stock Up in Pre-Market
IDEXX delivers year-over-year earnings and revenue growth in the first quarter of 2025.
Idexx Laboratories ( IDXX ) Beats Q1 Earnings Estimates
Idexx (IDXX) delivered earnings and revenue surprises of 1.37% and 1.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
